Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222247 · ClinicalTrials.gov registry record · Phase 3
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
A Phase 3 study, sponsored by The George Washington University Biostatistics Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,831
- Enrollment target
NCT01222247 is a Phase 3 study that has completed, run by The George Washington University Biostatistics Center. The registered enrollment target is 2,831 participants.
The verdict
NCT01222247, a Phase 3 study, has completed, sponsored by The George Washington University Biostatistics Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,831 participants
- Enrollment target
Study Summary
This is a randomized placebo controlled trial to evaluate whether antenatal corticosteroids can decrease the rate of neonatal respiratory support, thus decreasing the rate of NICU admissions and improving short-term outcomes in the late preterm infant. The use of antenatal corticosteroids has been shown to be beneficial in women at risk for preterm delivery prior to 34 weeks but has not been evaluated in those likely to deliver in the late preterm period
Interventions
- DRUG Placebo
- DRUG Betamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,831 participants |
| Start Date | 2010-10 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01222247
The ClinicalTrials.gov registry entry for NCT01222247 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,831 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The George Washington University Biostatistics Center, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01222247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01222247 about?
NCT01222247 is a clinical study titled "Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial". This is a randomized placebo controlled trial to evaluate whether antenatal corticosteroids can decrease the rate of neonatal respiratory support, thus decreasing the rate of NICU admissions and improving short-term outcomes in the late preterm infant. The use of antenatal corticosteroids has been s...
What is the current status of trial NCT01222247?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,831 participants. The study started on 2010-10. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT01222247?
The interventions under investigation include: Placebo (DRUG), Betamethasone (DRUG).
Who is sponsoring clinical trial NCT01222247?
This trial is sponsored by The George Washington University Biostatistics Center, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.